Distribution of HIV-1 subtypes in patients with HAART therapeutic failure in the States of Pará and Amazonas, Brazil: 2002 to 2006

Olinda Macêdo; Luciana Macêdo Ferreira; Carmen Andréa Freitas Lopes; Rita Catarina Medeiros de Sousa; José Ricardo Mourão Araújo; Pedro Fernando da Costa Vasconcelos

doi:10.5123/S2176-62232012000200002

Authors

Olinda Macêdo Seção de Virologia, Instituto Evandro Chagas/SVS/MS, Ananindeua, Pará, Brasil
Luciana Macêdo Ferreira Seção de Arbovirologia e Febres Hemorrágicas, Instituto Evandro Chagas/SVS/MS, Ananindeua, Pará, Brasil
Carmen Andréa Freitas Lopes Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém, Pará, Brasil
Rita Catarina Medeiros de Sousa Núcleo de Medicina Tropical, Universidade Federal do Pará, Belém, Pará, Brasil
José Ricardo Mourão Araújo Casa Dia Centro de Ats em Doenças Infecciosas Adquiridas, Belém, Pará, Brasil
Pedro Fernando da Costa Vasconcelos Seção de Arbovirologia e Febres Hemorrágicas, Instituto Evandro Chagas/SVS/MS, Ananindeua, Pará, Brasil

DOI:

https://doi.org/10.5123/S2176-62232012000200002

Keywords:

HIV-1, Subtypes, CF1 Recombinant Form, HAART Therapeutic Failure

Abstract

ABSTRACT

The aim of this study was to determine the distribution of HIV-1 subtypes in patients undergoing highly active antiretroviral therapy (HAART) therapeutic failure in Amazonas and Pará, two States in northern Brazil, from 2002 to 2006. This study was performed using plasma collected from individuals with human immunodeficiency virus-1 (HIV-1) and/or acquired immunodeficiency syndrome (AIDS) who were selected from the National Genotyping Network (Rede Nacional de Genotipagem - RENAGENO). From 2002 to 2006, a total of 127 plasma samples from the States of Amazonas and Pará, in northern Brazil, were obtained from AIDS and/or HIV-positive patients and subjected to genotyping and resistance testing using the ViroSeq^TM Genotyping System kit. Using the genetic information obtained from the HIV-1 protease and/or reverse transcriptase regions, HIV-1 subtype B was identified in 85% of the cases, followed by subtype F1 (4.6%) and the recombinant forms BF1 (4.6%) and CF1 (0.8%). The results of this study were similar to the results of other studies conducted in other regions of Brazil, with the exception of the detection of recombinant CF1, which was described for the first time in the Amazon Region.